Rho-Associated Kinase Inhibitor Fasudil Protects from Sepsis-Induced Acute Kidney Injury in Rat via Suppressing STAT-3 and NLRP-3 Pathway
- PMID: 40699739
- PMCID: PMC12110173
- DOI: 10.3390/cimb47050340
Rho-Associated Kinase Inhibitor Fasudil Protects from Sepsis-Induced Acute Kidney Injury in Rat via Suppressing STAT-3 and NLRP-3 Pathway
Abstract
Sepsis-associated acute kidney injury (S-AKI) is a severe complication in critically ill patients, marked by inflammation, oxidative stress, and renal dysfunction. This study aimed to evaluate the renoprotective effects of Fasudil (Fas), a Rho-associated kinase inhibitor, in a rat model of S-AKI induced by cecal ligation and puncture (CLP). Thirty-six Wistar albino rats were divided into control, CLP with saline, and Fas (100 mg/kg/day intraperitoneally) groups. Biochemical, histopathological, and molecular analyses were conducted to assess kidney function, oxidative stress, and inflammation. Fas treatment significantly decreased plasma malondialdehyde and TNF-α levels, reducing oxidative stress and systemic inflammation. Kidney function markers, including BUN and creatinine, showed marked improvement. Furthermore, Fas suppressed the expression of STAT-3 and NLRP-3 in renal tissues, highlighting its role in modulating key inflammatory pathways. Histological evaluation revealed alleviated renal damage, with less tubular necrosis and interstitial inflammation in the Fas-treated group. In conclusion, Fas demonstrates significant anti-inflammatory, antioxidant, and nephroprotective effects in S-AKI, primarily by inhibiting STAT-3 and NLRP-3 signaling. These results support its potential as a therapeutic agent in sepsis-induced kidney injury and suggest the need for further clinical evaluation.
Keywords: Fasudil; NLRP-3 inflammasome; Rho kinase inhibitor; STAT-3 pathway; sepsis-associated acute kidney injury.
Conflict of interest statement
The authors declare no conflicts of interest.
Figures



Similar articles
-
Effect of dapagliflozin on sepsis-induced kidney injury in a rat model: modulation of the NLRP3 pathway.Immunopharmacol Immunotoxicol. 2025 Aug;47(4):533-540. doi: 10.1080/08923973.2025.2519597. Epub 2025 Jun 18. Immunopharmacol Immunotoxicol. 2025. PMID: 40533406
-
Study on the modulation of kidney and liver function of rats with diabetic nephropathy by Huidouba through metabolomics.J Ethnopharmacol. 2025 Jul 24;351:120136. doi: 10.1016/j.jep.2025.120136. Epub 2025 Jun 11. J Ethnopharmacol. 2025. PMID: 40513925
-
JAK1/JAK2 inhibitor baricitinib ameliorates sepsis-induced acute kidney injury in rats.Eur J Pharmacol. 2025 Sep 5;1002:177770. doi: 10.1016/j.ejphar.2025.177770. Epub 2025 May 27. Eur J Pharmacol. 2025. PMID: 40441588
-
Management of urinary stones by experts in stone disease (ESD 2025).Arch Ital Urol Androl. 2025 Jun 30;97(2):14085. doi: 10.4081/aiua.2025.14085. Epub 2025 Jun 30. Arch Ital Urol Androl. 2025. PMID: 40583613 Review.
-
Hydroxyethyl starch (HES) versus other fluid therapies: effects on kidney function.Cochrane Database Syst Rev. 2013 Jul 23;2013(7):CD007594. doi: 10.1002/14651858.CD007594.pub3. Cochrane Database Syst Rev. 2013. PMID: 23881659 Free PMC article.
References
-
- Gómez H., Ince C., De Backer D., Pickkers P., Payen D., Hotchkiss J., Kellum J.A. A unified theory of sepsis-induced acute kidney injury: Inflammation, microcirculatory dysfunction, bioenergetics, and the tubular cell adaptation to injury. Shock. 2014;41:3–11. doi: 10.1097/SHK.0000000000000052. - DOI - PMC - PubMed
-
- Bellomo R., Ronco C., Kellum J.A., Mehta R.L., Palevsky P. Acute Dialysis Quality Initiative workgroup. Acute renal failure—Definition, outcome measures, animal models, fluid therapy and information technology, needs: The second international consensus conference of the acute dialysis quality initiative (ADQI) group. Crit. Care. 2004;8:R204–R212. doi: 10.1186/cc2872. - DOI - PMC - PubMed
-
- Okada A., Fukushima K., Fujita M., Nakanishi M., Hamori M., Nishimura A., Shibata N., Sugioka N. Alterations in cisplatin pharmacokinetics and its acute/sub-chronic kidney injury over multiple cycles of cisplatin treatment in rats. Biol. Pharm. Bull. 2017;40:1948–1955. doi: 10.1248/bpb.b17-00499. - DOI - PubMed
LinkOut - more resources
Full Text Sources
Research Materials
Miscellaneous